Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice

Biological Chemistry

Volumn 385, Issue 9, 2004, Pages 845-852

  Irwin, Nigel ^a   Gault, Victor A ^a   Green, Brian D ^a   Greer, Brett ^b   McCluskey, Jane T ^a   Harriott, Patrick ^b   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

(Pro3)GIP; Enteroinsular axis; GIP receptor antagonist

Indexed keywords

GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL STRUCTURE; CONTROLLED STUDY; ENZYME SPECIFICITY; ENZYME STABILITY; FEEDING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PANCREAS ISLET CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; BLOOD GLUCOSE; GASTRIC INHIBITORY POLYPEPTIDE; HOMEOSTASIS; INSULIN; ISLETS OF LANGERHANS; MICE; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 5044229968     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2004.110     Document Type: Article

References (36)

1. Brown, J.C. (1994). Enteroinsular axis. In: Gut Peptides: Biochemistry and Physiology, G.J. Dockray and J.H. Walsh, eds. (New York, USA: Raven Press), pp. 765-784.
2. Bunn, H.F., Haney, D.N., Gabbay, K.H., and Gallop, P.M. (1975). Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochem. Biophys. Res. Commun. 67, 103-109.
3. Burington, R.S. (1973). Handbook of Mathematical Tables and Formulae (New York, USA: McGraw-Hill).
4. Creutzfeldt, W. (2001). The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109, S288-303.
5. Dupré, J., Ross, S.A., Watson, D., and Brown, J.C. (1973). Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37, 826-828.
6. Eckel, R.H., Fujimoto, W.Y., and Brunzell, J.D. (1979). Gastric inhibitory polypeptide enhanced lipoprotein activity in cultured preadipocytes. Diabetes 28, 1141-1142.
7. Ehses, J.A., Casilla, V.R., Doty, T., Pospisilik, J.A., Winter, K.D., Demuth, H.U., Pederson, R.A., and McIntosh, C.H.S. (2003). Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144, 4433-4445.
8. Elahi, D., Meneilly, G.S., Minaker, K.L., Rowe, J.W., and Andersen, D.K. (1986). Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Abstracts presented at the sixth international symposium on gastrointestinal hormones in Vancouver, BC, Canada. Can. J. Physiol. Pharmacol. 65, pp. 18.
9. Fehmann, H.C., Göke, R., and Göke, B. (1995). Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocrinol. Rev. 16, 390-410.
10. Flatt, P.R., and Bailey, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577.
11. Gault, V.A., O'Harte, F.P.M., Harriott, P., and Flatt, P.R. (2002a). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290, 1420-1426.
12. 1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Blochem. J. 367, 913-920.
13. 3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic ob/ob mice: evidence that GIP is the major physiological incretin. Diabetologia 46, 222-230.
14. Gault, V.A., Flatt, P.R., and O'Harte, F.P.M. (2003b). Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. 308, 207-213.
15. Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2003c). Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 37, 253-263.
16. Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F., and Drucker, D.J. (2004). Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53, 1326-1335.
17. Hinke, S.A., Lynn, F., Ehses, J., Pamir, N., Manhart, S., Kuhn-Wache, K., Rosche, F., Demuth, H.U., Pederson, R.A., and McIntosh, C.H.S. (2003). Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. Adv. Exp. Med. Biol. 524, 293-301.
18. Holst, J.J. (1994). Glucagon-like peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107, 1848-1855.
19. Holst, J.J. (2002). Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1? BioDrugs 16, 175-181.
20. Kieffer, T.J. (2003). GIP or not GIP? That is the question. Trends Pharmacol. Sci. 24, 110-112.
21. Knapper, J.M., Puddicombe, S.M., Morgan, L.M., and Fletcher, J.M. (1995). Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36) amide on lipoprotein lipase activity in explants of rat adipose tissue. J. Nutr. 125, 183-188.
22. Kosaka, T., and Lim, R.K.S. (1930). Demonstration of the humoral agent in fat inhibition of gastric secretion. Proc. Soc. Exp. Biol. Med. 27, 890-891.
23. Meier, J.J., Nauck, M.A., Schmidt, W.E., and Gallwitz, B. (2002). Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 107, 1-13.
24. Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A. et al. (1999). Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Nat. Acad. Sci. USA 96, 14843-14847.
25. Nauck, M., Schmidt, W.E., Ebert, R., Strietzel, J., Cantor, P., Hoffmann, G., and Creutzfeldt, W. (1989). Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J. Clin. Endocrinol. Metab. 69, 654-662.
26. Oben, J., Morgan, L.M., Fletcher, J., and Marks, V. (1991). Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 130, 267-272.
27. O'Harte, F.P.M., Gray, A.M., and Flatt, P.R. (1998) Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. J. Endocrinol. 156, 237-243.
28. Pamir, N., Lynn, F.C., Buchan, A.M., Ehses, J., Hinke, S.A., Pospisilik, J.A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C.H.S., and Pederson, R.A. (2003). Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab. 284, E931-939.
29. Pederson, R.A., Satkunarajah, M., McIntosh, C.H.S., Scrocchi, L.A., Flamez, D., Schuit, F., Drucker, D.J., and Wheeler, M.B. (1998). Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon hke peptide 1 receptor -/- mice. Diabetes 47, 1046-1052.
30. Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D.J., Wollheim, C., Burcelin, R., and Thorens, B. (2004). Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest. 113, 635-645.
31. Stevens, J.F. (1971). Determination of glucose by an automatic analyser. Clin. Chem. Acta 32, 199-201.
32. Trumper, A., Trumper, K., Trusheim, H., Arnold, R., Göke, B., and Horsch, D. (2001). Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15, 1559-1570.
33. Trumper, A., Trumper, K., and Horsch, D. (2002). Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells. J. Endocrinol. 174, 233-246.
34. Tseng, C-C., Boylan, M.O., Jarboe, L.A., Usdin, T.B., and Wolfe, M.M. (1996). Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am. J. Physiol. 270, E661-E666.
35. Wang, Y., Montrose-Rafizadeh, C., Adams, L., Raygada, M., Nadiv, O., and Egan, J.M. (1996). GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol. Cell Endocrinol. 116, 81-87.
36. Yip, R.G.C., Boylan, M.O., Kieffer, T.J., and Wolfe, M.M. (1998). Functional GIP receptors are present on adipocytes. Endocrinology 139, 4004-4007.